- Home
- DUK vs VRTX Comparison
DUK vs VRTX Comparison
Compare DUK & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DUK
- VRTX
- Stock Information
- Founded
- DUK 1904
- VRTX 1989
- Country
- DUK United States
- VRTX United States
- Employees
- DUK N/A
- VRTX N/A
- Industry
- DUK Railroads
- VRTX EDP Services
- Sector
- DUK Industrials
- VRTX Technology
- Exchange
- DUK Nasdaq
- VRTX Nasdaq
- Market Cap
- DUK 95.7B
- VRTX 96.6B
- IPO Year
- DUK N/A
- VRTX 1991
- Fundamental
- Price
- DUK $125.19
- VRTX $410.82
- Analyst Decision
- DUK Buy
- VRTX Buy
- Analyst Count
- DUK 15
- VRTX 25
- Target Price
- DUK $133.08
- VRTX $493.64
- AVG Volume (30 Days)
- DUK 2.7M
- VRTX 1.7M
- Earning Date
- DUK 11-07-2025
- VRTX 11-03-2025
- Dividend Yield
- DUK 3.39%
- VRTX N/A
- EPS Growth
- DUK 12.93
- VRTX N/A
- EPS
- DUK 6.13
- VRTX 14.07
- Revenue
- DUK $30,848,000,000.00
- VRTX $11,418,800,000.00
- Revenue This Year
- DUK $7.23
- VRTX $10.90
- Revenue Next Year
- DUK $3.33
- VRTX $9.57
- P/E Ratio
- DUK $20.48
- VRTX $29.16
- Revenue Growth
- DUK 4.25
- VRTX 10.46
- 52 Week Low
- DUK $105.20
- VRTX $362.50
- 52 Week High
- DUK $127.85
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- DUK 61.30
- VRTX 61.10
- Support Level
- DUK $120.94
- VRTX $400.74
- Resistance Level
- DUK $123.93
- VRTX $411.91
- Average True Range (ATR)
- DUK 1.54
- VRTX 8.84
- MACD
- DUK 0.29
- VRTX 3.92
- Stochastic Oscillator
- DUK 88.34
- VRTX 97.78
About DUK Duke Energy Corporation (Holding Company)
Duke Energy is one of the largest US utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to more than 8 million customers. Its natural gas utilities serve more than 1.6 million customers.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.